ArticleJournal of neuro-oncology2025
Advancements in adaptive MR-guided radiotherapy for high-grade gliomas.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A two-stage model combining clinical and delta-radiomics features for prognosis in high-grade gliomas after chemoradiotherapy: a retrospective study.La Radiologia medica · 2026Article
- A Comparative Study of Five Target Volume Definitions for Radiotherapy in Glioblastoma Multiforme.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is the most common primary malignancy of the central nervous system, with a poor prognosis despite multimodal treatment approaches. With the development and integration of Magnetic Resonance-guided Linear Accelerator (MR-Linac) technology into the treatment paradigm for high-grade gliomas, there is promising potential for improved treatment precision and reduced side effects for patients diagnosed with this aggressive cancer. The MR-Linac combines high-resolution, real-time magnetic resonance imaging with precise linear accelerator-based treatment delivery, enabling adaptive radiotherapy that adjusts to anatomical changes during the treatment course. This technology offers the potential to refine target delineation, optimize treatment volumes, and reduce radiation exposure to healthy tissue. The editorial discusses the transformative potential of the MR-Linac in improving treatment personalization and outcomes for patients with high-grade gliomas, positioning it as a significant advancement in radiation oncology.
Indexed as
Identifiers
40272746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.